About 3DHEALS Company Directory:

3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members. 


Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

Organization Name
Headquater location

Prellis Biologics

Harnessing the power of the human immune system to build next-generation medicines.

Headquarters Hayward San Francisco CA 94545 United States
Categories: Bioprinting /Biofabrication, Pitch3D
CEO: Melanie Matheu


Prellis Biologics, Inc. has solved the final hurdle in human tissue engineering: rapid production of extracellular matrix and capillaries. ​From biologically compatible materials we build vascularized tissue structures and extracellular matrix to grow human tissues and cells. Our combined speed and resolutions are unmatched by any other manufacturing process. Prellis engineers and cell biologists have worked closely together to demonstrate numerous applications of ultra-fast biocompatible 3D printing, including (but not limited to) large format tumors, stem cells, and neurons. The ability to build complex, large format tissues in the laboratory has numerous applications that range from therapeutics R&D to transplant models, and reproducing an organ from a patient’s own cells.  ​

Since the COVID-19 pandemic, the company appears to have pivoted to focus more on 3D bioprinted lymph nodes for drug discovery and developement. Prellis’ Externalized Immune System (EXIS™) platform recreates human immunobiology in vitro in the form of lymph node organoids (LNOs™). 3D printed LNOs™ allow direct access to a fully functional human immune system for antibody discovery, immunogenicity evaluation, and vaccine development.

Prellis’ proprietary, industry-leading two-photon 3D printing technology supports large, complex tumor co-culture systems mimicking tumor microenvironments, enabling the interrogation of interactive biological systems for uniquely relevant prioritization of immuno-oncology therapeutics.